People · Operator
Named in public records as an officer, director or promoter · active 2009–2013 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Clovis Oncology, Inc. | — | Pharmaceuticals | Series D+ | $358.3M | $6.8B | 2009 |
Andrew R. Allen at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Andrew R. Allen on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| James C. Blair | 1 | 8 |
| Brian G. Atwood | 1 | 8 |
| Erle T. Mast | 1 | 3 |
| Patrick J. Mahaffy | 1 | 2 |
| Ginger L. Graham | 1 | 2 |
| Keith L. Flaherty | 1 | 1 |
| Thorlef J. Spickschen | 1 | 1 |
| Edward J. McKinley | 1 | 1 |
| Gillian C. Ivers-Read | 1 | 1 |
| Paul C. Klingenstein | 1 | 1 |
| Steven L. Hoerter | 1 | 1 |
| M. James Barret | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.